2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-20558
    D-(+)-Malic acid 636-61-3 ≥98.0%
    D-(+)-Malic acid (D-Malic acid), an active enantiomer of Malic acid, is a competitive inhibitor of L(--)malic acid transport.
    D-(+)-Malic acid
  • HY-A0030
    Fesoterodine fumarate 286930-03-8 99.52%
    Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB).
    Fesoterodine fumarate
  • HY-B0747
    Eicosapentaenoic acid ethyl ester 86227-47-6 98.0%
    Eicosapentaenoic acid ethyl ester (EPA ethyl ester) is an orally active ω-3 fatty acid agent. Eicosapentaenoic acid ethyl ester could improve the activity of liver β-oxidase in vitro, reduce the level of liver total triglyceride, increase the content of liver triglyceride and phospholipid ω-3 fatty acid, and increase the total ω-3 fatty acid level in rats.
    Eicosapentaenoic acid ethyl ester
  • HY-D1445
    LysoSensor PDMPO 98.05%
    PDMPO, a lysosome pH indicator, is an excellent fluorescent acidotropic reagent for fluorescence imaging. PDMPO is a potent tool with which to study acidic organelles of live cells. PDMPO exhibits pH-dependent dual-excitation and dual-emission spectral peaks. PDMPO produces a blue fluorescence in weakly acidic organelles and shifts to yellow in more acidic lysosomes. (Abs=329 nm; Em=440/540 nm).
    LysoSensor PDMPO
  • HY-N0732
    Jolkinolide B 37905-08-1 99.65%
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
    Jolkinolide B
  • HY-N0762
    Isobavachin 31524-62-6 99.88%
    Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease.
    Isobavachin
  • HY-N4075
    O-Desmethylangolensin 21255-69-6 98.54%
    O-Desmethylangolensin is a metabolite of soy isoflavone, daidzein metabolized by gut microbiota. O-Desmethylangolensin possesses antioxidant activity.
    O-Desmethylangolensin
  • HY-N5011
    5,7-Dimethoxyflavone 21392-57-4 99.86%
    5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome P450 (CYP) 3As. 5,7-Dimethoxyflavone is also a potent Breast Cancer Resistance Protein (BCRP) inhibitor.
    5,7-Dimethoxyflavone
  • HY-N6678
    Zearalanone 5975-78-0 99.60%
    Zearalanone is a reductive metabolite of Zearalenone (HY-103447). Zearalanone binds to serum albumin across multiple species. Zearalanone enhances the binding affinity of Warfarin (HY-B0687) to serum albumin.
    Zearalanone
  • HY-N6833
    Rebaudioside M 1220616-44-3 99.81%
    Rebaudioside M, a glycoside of the ent-kaurene diterpenoid aglycone, is a non-calorie sweetener isolated from Stevia rebaudiana. Rebaudioside M has antidiabetics, antihypertension, anti-inflammatory, antioxidant, anticaries and anticancer benefits. Rebaudioside M is more than 350 times sweeter than sucrose. Rebaudioside M can be used in food and beverage .
    Rebaudioside M
  • HY-P2857
    Glucoamylase, Aspergillus niger 9032-08-0
    Amyloglucosidase, Aspergillus niger (Amyloglucosidase, Aspergillus niger) is a starch-hydrolyzing enzyme with high catalytic efficiency towards soluble starch and raw starch. Amyloglucosidase, Aspergillus niger hydrolyzes α-1,4 and α-1,6 glycosidic linkages in starch and similar substrates, and primarily releases β-glucose molecules from the non-reducing ends. Amyloglucosidase, Aspergillus niger participates in glycogen metabolism and is associated with type II glycogen storage disease. Amyloglucosidase, Aspergillus niger converts starch into glucose, and is applicable to the industrial production of high-fructose syrup, ethanol and other fermented products.
    Glucoamylase, Aspergillus niger
  • HY-100618
    Hispidin 555-55-5 99.85%
    Hispidin, a PKC inhibitor and a phenolic compound can be found in Phellinus linteus, has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties.
    Hispidin
  • HY-106697
    Ponalrestat 72702-95-5 99.51%
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
    Ponalrestat
  • HY-111827
    S-1-Propenyl-L-cysteine 52438-09-2 99.91%
    S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model. S-1-Propenyl-L-cysteine exhibits antioxidative efficacy through a NO-dependent BACH1 signaling pathway. S-1-Propenyl-L-cysteine is orally active.
    S-1-Propenyl-L-cysteine
  • HY-112945
    MLS0315771 727664-91-7 99.46%
    MLS0315771 is a potent and biologically active competitive phosphomannose isomerase (MPI) inhibitor, with an IC50 ~1 μM and a Ki of 1.4 μM.
    MLS0315771
  • HY-113162
    Bovinic acid 2540-56-9 ≥99.0%
    Bovinic acid is an orally active anti-inflammatory agent. Bovinic acid inhibits oxidative stress and ferroptosis by regulating the Keap1-Nrf2 signaling pathway. Bovinic acid exerts hepatoprotective effects against alcohol-associated liver disease. Bovinic acid can be used for the research of alcohol-associated liver disease.
    Bovinic acid
  • HY-113338
    8-Hydroxyguanine 5614-64-2 ≥98.0%
    8-Hydroxyguanine is a DNA damage product under oxidative stress, which is formed when hydroxyl radicals attack guanine in DNA. 8-Hydroxyguanine induces mutagenesis and leads to a transversion from G to T. 8-Hydroxyguanine is a marker of DNA oxidative damage.
    8-Hydroxyguanine
  • HY-158127
    FABP1-IN-1 3048021-44-6 99.95%
    FABP1-IN-1 (44) is a selective FABP1 inhibitor, with an IC50 of 4.46 μM. FABP1-IN-1 (44) can be used for the research of NASH.
    FABP1-IN-1
  • HY-A0118A
    Naloxegol oxalate 1354744-91-4 99.91%
    Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target Ki of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation.
    Naloxegol oxalate
  • HY-N0378R
    D-Mannitol (Standard) 69-65-8 99.96%
    D-Mannitol (Standard) is the analytical standard of D-Mannitol (HY-N0378). This product is intended for research and analytical applications. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells. D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed.
    D-Mannitol (Standard)
Cat. No. Product Name / Synonyms Application Reactivity